These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8906291)

  • 1. Eosinophilia-myalgia syndrome. Status of patients at onset and after four years of disease.
    Criswell LA; Pincus T
    Adv Exp Med Biol; 1996; 398():371-2. PubMed ID: 8906291
    [No Abstract]   [Full Text] [Related]  

  • 2. The eosinophilia-myalgia syndrome: what we know, what we think we know, and what we need to know.
    Clauw DJ; Pincus T
    J Rheumatol Suppl; 1996 Oct; 46():2-6. PubMed ID: 8895175
    [No Abstract]   [Full Text] [Related]  

  • 3. Eosinophilia-myalgia syndrome: patient status 2-4 years after onset.
    Pincus T
    J Rheumatol Suppl; 1996 Oct; 46():19-24; discussion 24-5. PubMed ID: 8895178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Criteria for the definition of the eosinophilia-myalgia syndrome.
    Hertzman PA
    J Rheumatol Suppl; 1996 Oct; 46():7-12. PubMed ID: 8895176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2 years after onset.
    Hertzman PA; Clauw DJ; Kaufman LD; Varga J; Silver RM; Thacker HL; Mease P; Espinoza LR; Pincus T
    Ann Intern Med; 1995 Jun; 122(11):851-5. PubMed ID: 7741371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive dysfunction in the eosinophilia-myalgia syndrome.
    Krupp LB; Masur DM; Kaufman LD
    Neurology; 1993 May; 43(5):931-6. PubMed ID: 8492948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Centers for Disease Control and Prevention criteria for the eosinophilia-myalgia syndrome in a geographically defined population.
    Spitzer WO; Haggerty JL; Berkson L; Davis W; Palmer W; Tamblyn R; Laprise R; Mulder LJ
    J Rheumatol Suppl; 1996 Oct; 46():73-9; discussion 79-80. PubMed ID: 8895183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Eosinophilia-myalgia syndrome].
    Kotake S; Kashiwazaki S
    Nihon Rinsho; 1992 Jul; 50(7):1650-5. PubMed ID: 1404896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinophilia-myalgia syndrome or fibromyalgia with eosinophilia?
    Hudson JI; Pope HG; Daniels SR; Horwitz RI
    JAMA; 1993 Jun 23-30; 269(24):3108-9. PubMed ID: 8505810
    [No Abstract]   [Full Text] [Related]  

  • 10. Upper extremity contractures in a patient with eosinophilia-myalgia syndrome.
    Marchman HB; Gleason CB; Shaw JC
    Arch Phys Med Rehabil; 1991 Nov; 72(12):1029-30. PubMed ID: 1953317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of the eosinophilia-myalgia syndrome.
    Culpepper RC; Williams RG; Mease PJ; Koepsell TD; Kobayashi JM
    Ann Intern Med; 1991 Sep; 115(6):437-42. PubMed ID: 1651673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A lesson on the purity of pharmaceutical products derived from biotechnology: eosinophilia-myalgia syndrome].
    Boll Chim Farm; 1995; 134(7):394-5. PubMed ID: 7546544
    [No Abstract]   [Full Text] [Related]  

  • 13. [Scleroderma and environment. III. Eosinophilia-myalgia syndrome and L-tryptophan].
    Bournerias I; Castot A
    Ann Dermatol Venereol; 1991; 118(12):962-8. PubMed ID: 1799247
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic immune activation in the eosinophilia-myalgia syndrome.
    McKinley KL; Harati Y; Schneider LW
    Muscle Nerve; 1993 Sep; 16(9):947-51. PubMed ID: 8355725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophilia myalgia syndrome. The role of contaminants, the role of serotonergic metabolism set up.
    Nicolodi M; Sicuteri F
    Adv Exp Med Biol; 1996; 398():351-7. PubMed ID: 8906288
    [No Abstract]   [Full Text] [Related]  

  • 16. Abnormalities of the coronary arteries, neural structures and conduction system of the heart observed postmortem in the eosinophilia-myalgia syndrome, with a discussion of comparative findings from the toxic oil syndrome.
    James TN
    Trans Am Clin Climatol Assoc; 1991; 102():52-81; discussion 81-3. PubMed ID: 2130570
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibromyalgia, psychiatric disorders, and assessment of the longterm outcome of eosinophilia-myalgia syndrome.
    Hudson JI; Pope HG; Carter WP; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():37-42; discussion 42-3. PubMed ID: 8895180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pain, fatigue, and sleep in eosinophilia-myalgia syndrome: relationship to neuropsychological performance.
    Pollina DA; Kaufman LD; Masur DM; Krupp LB
    J Neuropsychiatry Clin Neurosci; 1998; 10(3):338-42. PubMed ID: 9706542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophilia-myalgia syndrome: description of an unusual case.
    Giordano N; Senesi M; Monaco R; Palumbo F; Battisti E; Nardi P; Mattii G; Gennari C
    Clin Exp Rheumatol; 1997; 15(2):222-3. PubMed ID: 9196880
    [No Abstract]   [Full Text] [Related]  

  • 20. The eosinophilia-myalgia syndrome and tryptophan.
    Belongia EA; Mayeno AN; Osterholm MT
    Annu Rev Nutr; 1992; 12():235-56. PubMed ID: 1503805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.